TTTaner Tan

Taner Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taner Tan has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transplant-Associated Decline in Pectoral Muscle Density Following Autologous Hematopoietic Stem Cell Transplantation: A Longitudinal CT-Based Study

    by Taner Tan, Zeynep Atceken, Efe Semercioğlu, Erdem Çığ, Ahmet Umur Topçu, Sinem Civriz Bozdağ

    Background and Objectives: Autologous hematopoietic stem cell transplantation (AHSCT) can lead to skeletal muscle loss owing to the catabolic state and inflammatory burden it induces. Pectoral muscle density (PMD), measured on thoracic CT, is a valuable indicator for assessing muscle composition and quality. However, its time-dependent change during AHSCT and the early post-transplant period, as well as its prognostic value, remain insufficiently defined. This study evaluated the dynamic changes in PMD following AHSCT and the clinical relevance of pre-transplant PMD. Materials and Methods: This single-center retrospective study included patients who underwent AHSCT between January 2022 and December 2024 and had a pre-transplant thoracic CT scan available. Patients with both pre- and post-transplant thoracic CT images constituted the longitudinal subgroup in which the dynamic change in PMD was assessed. PMD was measured in Hounsfield units (HU) on non-contrast CT, on a single axial slice immediately above the aortic arch using a 1-cm2 region of interest, taking the average of three measurements. The primary endpoint was the change in PMD between the pre- and post-transplant scans; secondary endpoints were length of hospital stay, neutrophil and platelet engraftment, and overall survival. Paired t-tests, Wilcoxon signed-rank and Mann–Whitney U tests, Spearman correlation, multivariable linear regression, and Cox proportional hazards and Kaplan–Meier analyses were used. Results: 142 patients (57.0% male; mean age 53.5 ± 14.9 years; multiple myeloma 43.7%, non-Hodgkin lymphoma 38.0%, Hodgkin lymphoma 14.1%) were analyzed; mean pre-transplant PMD was 52.95 ± 9.66 HU. In the longitudinal subgroup (n = 79; post-transplant CT at a median of day +12), PMD declined in 96.2% of patients, from 52.80 ± 9.22 to 41.99 ± 9.21 HU (mean reduction 10.81 HU; 95% CI 9.19–12.43; p < 0.001; Cohen’s dz = 1.50; mean change −20.27 ± 13.36%). The decline was independent of the inter-scan interval, sex, age, and diagnosis. Lower PMD correlated with older age (ρ = −0.281, p < 0.001) and differed by underlying diagnosis (p = 0.022). Patients with pre-transplant PMD ≤ 60 HU had a longer mean hospital stay than those with PMD > 60 HU (19.6 vs. 16.4 days); however, this difference was not significant in non-parametric (p = 0.33) or multivariable analyses (p = 0.25). Baseline PMD was not significantly associated with engraftment or overall survival (HR per 10-HU decrease 1.35; 95% CI 0.91–2.00; p = 0.14). Conclusions: A marked and consistent decline in pectoral muscle density occurs in the early period following AHSCT, irrespective of scan timing, sex, age, or diagnosis. Baseline PMD was not significantly associated with engraftment, hospitalization, or survival, although numerical trends toward longer hospitalization and poorer survival were observed with lower PMD. PMD, obtainable from routine non-contrast thoracic CT, may serve as a marker of transplant-related changes in muscle quality, and its prognostic value warrants prospective evaluation.

  • Open Access

    Nutritional Risk, Weight Loss, and Inflammatory Profiles During Autologous Stem Cell Transplantation: Clinical Correlates in Patients with Lymphoma and Multiple Myeloma

    by Berrin Balik, Defne Beybolat, Osama Alabdullah, Hande Erkaya, Nur I. Genc, Barıs Gerenli, Elif Ertas, Zeynep Atceken, Tugce Aytulu, Taner Tan, et al.

    Background/Objectives: Nutritional deterioration during autologous stem cell transplantation (ASCT) is driven by conditioning-related gastrointestinal toxicity, reduced oral intake, inflammatory stress, and catabolism. We evaluated the relationships among NRS-2002 nutritional risk, admission-to-discharge change in measured body weight, nutrition-impact symptoms, inflammatory markers, and clinical characteristics in patients with lymphoma and multiple myeloma. Methods: This retrospective, single-center observational cohort included 131 adults undergoing ASCT for lymphoma (n = 74) or multiple myeloma (n = 57) between 2022 and 2024. Nutritional risk was assessed at admission using NRS-2002, and measured body-weight change, albumin, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), nutritional support, nutrition-impact symptoms, and length of stay were evaluated. A ≥5% reduction in measured body weight was used as a pragmatic exploratory threshold, not as a diagnostic malnutrition criterion. Results: High nutritional risk (NRS-2002 ≥ 3) was present in 33/131 patients (25%), while 118/131 (90%) had a lower measured discharge weight and 53/131 (40%) met the ≥5% threshold. NRS-2002 was not significantly associated with CRP, albumin, NLR, percentage measured body-weight reduction, or length of stay. In exploratory multivariable analysis (complete-case n = 92; 37 events), multiple myeloma was associated with lower odds of meeting the threshold than lymphoma (OR, 0.20; 95% CI, 0.07–0.56; p = 0.002), whereas higher admission BMI was associated with higher odds (OR, 1.12 per kg/m2; 95% CI, 1.01–1.24; p = 0.03). A continuous-outcome model also showed less measured body-weight reduction in multiple myeloma (β, −1.9 percentage points; p = 0.005), while the BMI association was borderline (p = 0.051). Conclusions: Reductions in measured body weight and nutrition-impact symptoms were common during ASCT. Because detailed fluid-related data were unavailable, measured weight change cannot be assumed to represent tissue loss. Admission NRS-2002 screening and subsequent acute weight change are related but distinct assessments. The diagnosis association may reflect unmeasured transplant-related differences, and the BMI association was not robust in sensitivity analyses.

  • Open Access

    Determinants of Mediastinal Lymph Node Attenuation on Non-Contrast Chest Computed Tomography

    by Zeynep Atceken, Erdem Cig, Yuksel Peker, Taner Tan

    Objective: To investigate clinical determinants of mediastinal lymph node attenuation (MLNA) on non-contrast chest computed tomography (CT), focusing on smoking history and cardiometabolic factors. Methods: In this retrospective single-center study, individuals undergoing non-contrast chest CT without known cardiopulmonary disease were included. MLNA was measured in Hounsfield units (HU) from the largest visible mediastinal lymph node. Smoking status (ever vs never), age, sex, hypertension, diabetes mellitus, and body mass index were recorded. Multivariable linear regression identified independent predictors of MLNA. Receiver operating characteristic (ROC) analysis evaluated attenuation for discriminating smoking history. Results: A total of 138 individuals were analyzed (82 ever smokers, 56 never smokers). MLNA was higher in ever smokers than never smokers (median 39.5 vs 35 HU, P=0.001). In multivariable analysis, smoking history remained independently associated with increased attenuation (B=5.48 HU, 95% confidence interval [CI]: 1.72–9.23, P=0.005). Age (B=0.33 HU/year, P<0.001), hypertension (B=6.55 HU, P=0.009), and diabetes mellitus (B=5.93 HU, P=0.043) were also independent predictors, whereas sex and BMI were not significant. The model explained 41% of attenuation variance (R²=0.41). ROC analysis demonstrated moderate discrimination for smoking history (area under curve [AUC] = 0.66; optimal cut-off 46 HU, specificity of 89.3%). Attenuation values were highest among current smokers in exploratory analyses. Conclusion: Smoking history, age, hypertension, and diabetes mellitus are independently associated with increased mediastinal lymph node attenuation on non-contrast CT. Elevated attenuation may reflect chronic inflammatory activation, fibrotic remodeling, and cumulative cardiometabolic tissue injury rather than overt pathology, supporting its role as a contextual imaging marker in risk-aware radiologic interpretation.

  • Open Access

    A Large Room for Improvement Concerning the Management of Relapsed Refractory Large B-cell Lymphoma in Türkiye: Real-World Outcomes in the Setting Without Access to T-Cell Redirecting Therapies

    by Umut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, Elif Birtaş Ateşoğlu, Fatma Keklik Karadağ, Meral Uluköylü Mengüç, Esra Terzi Demirsoy, Simge Erdem, Ebru Pekgüç, Taner Tan, et al.

    Large B-cell lymphoma (LBCL) patients who fail frontline therapy (R/R-LBCL) experience highly unfavorable outcomes. The development of T-cell redirecting therapies is rapidly evolving this outlook. However, costs and infrastructural challenges limit access to such innovative therapies. This study was conducted to document the shortcomings of management in the absence of regular access to T-cell redirecting therapies in a contemporary patient population and define subgroups with the most urgent need for accessing innovative treatments. The second-line management and outcomes of a large real-world LBCL cohort from Türkiye were retrospectively analyzed with the participation of nine centers from four different geographical regions. Despite the contemporary period (2012-24), there was no regular access to novel agents. The median PFS-2 was 6.9 months. Less than a quarter of patients (24.3%) received transplantation following a response to second-line therapy, the only subgroup who benefited from the standard care (2-year PFS-2: 67.8%). The remaining 295 patients (75.7% of the cohort) had a median survival of 6.1 months and a 2-year PFS-2 of 10.3%. Progression within a year from diagnosis, non-curative intent at second line, and failure of curative second-line therapy were key adverse features for a dismal prognosis, with median survival durations of 8.8, 2, and 7.4 months, respectively. The current therapeutic strategy of intensive chemoimmunotherapy followed by autologous transplantation yields a reasonable chance of survival for only a fifth of patients. The findings emphasize the urgent need for expanding access to T-cell redirecting approaches in R/R LBCL for early progressors, transplant-ineligible cases, those who fail intensive second-line regimens.


  • Allojenik Kök Hücre Naklinde EASIX’in Prognostik Rolü: Tek Merkezden Retrospektif Bulgular

    by Taner Tan, Ahmet Umur Topcu, Erdem Çiğ, Efe Semerci̇oĞlu, Emre Osmanbaşoğlu, Ümit Barbaros Üre, Olga Meltem Akay, Sinem Ci̇vRi̇z Bozdağ

  • Pancreatic Plasmacytoma Post-Allogeneic-HSCT: Diagnosis by EUS-Guided Biopsy

    by Taner Tan, Ahmet Umur Topçu, Emre Osmanbaşoğlu, Emrah Alper, Olga Meltem Akay, Sinem Civriz Bozdağ

  • Open Access

    Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B‐cell lymphoma cohort

    by Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Uğur Hatipoğlu, Meral Uluköylü Mengüç, Ebru Pekgüç, Taner Tan, Eda Nuhoğlu Kantarcı, Metban Mastanzade, Ali Durdu, et al.

    Summary: Comparative first‐line trials in large B‐cell lymphoma (LBCL) have mostly failed over the last decade. Failures were commonly attributed to overestimation of the progression risk for the control arms, bringing the precision of the international prognostic index (IPI) into scrutiny. Simplified molecular IPI (smIPI), introduced at American Society of Hematology 2023, was developed to address the shortcomings of IPI. This study investigated smIPI and its potential implications as trial eligibility criteria among a multicentre LBCL cohort of 1439 patients. Patients diagnosed between 2012 and 2024 were included. Data were collected from institutional archives. The primary end‐point was risk stratification for progression‐free survival (PFS). Kaplan–Meier and Cox regression methods were used for survival analyses. The smIPI reclassified 38.2% and 5.3% of patients to higher and lower risk groups from IPI, respectively. Patients reclassified to higher risk groups by smIPI had an increased risk of progression than the rest of the group (hazard ratio = 1.34, p = 0.003). High‐risk groups classified by IPI and smIPI had similar outcomes (3‐year PFS 54.9% vs. 56.3%); however, the high‐risk group size was expanded by 35.2% when defined by smIPI. The smIPI is easily applicable and more sensitive than IPI in identifying patients under high risk of progression who are ideal candidates to participate in clinical research.


  • Open Access

    Decoding Cytoplasmic Vacuolization: Unravelling the Diagnostic Challenges of Vexas Syndrome

    by Taner Tan, Mustafa Cem Bülbül, Merve Kaysin, İbrahim Öner Doğan, Olga Meltem Akay, Sinem Cıvrız Bozdağ

  • Open Access

    Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML

    by Taner Tan, Genco Gençdal, Ümit Barbaros Üre, Olga Meltem Akay


  • Open Access

    Can bispecific antibody therapies for multiple myeloma be a risk factor for the development of secondary haemotopoietic malignancy? A case report

    by Taner Tan, İbrahim Öner Doğan, Sinem Civriz Bozdağ

    With the introduction of many new treatments in multiple myeloma and the effective use of autologous stem cell transplantation, significant prolongation of overall survival has been achieved. Despite this ,there is still no cure for this disease. Relapses/refractory conditions seen after multiple treatments have brought the use of new agents to the agenda. Elranatamab is a humanized bispecific antibody used in relapsed or refractory multiple myeloma which targets B-cell maturation antigen on myeloma cells and CD3 on T cells . With this mechanism, elranatamab could activate T cells to induce cytotoxic T-cell response against myeloma cells. (1) Although we have an idea and experience about the short-term adverse effect profile and management, our ideas about the long-term adverse effect and safety profile are not yet clear due to the fact that it is a very new agent. We described an unexpected hematologic event during the use of elranatamab in the following case.